Research progress in molecular targeted therapy for pancreatic cancer
Pancreatic cancer is one of most malignant tumors with extremely poor prognosis, and the 5-year survival rate of the patients is below 5%. Conventional treatments produce very limited effects for pancreatic cancer, and it requires multidisciplinary approach and comprehensive management. With the deepening knowledge of molecular biology, molecular targeted drugs such as epidermal growth factor receptor inhibitors have shown impressive potential in treatment of pancreatic cancer. Here, the authors present the current status and progress in molecular targeted drug research for pancreatic cancer.